5 Apr '16
Russia’s Kazan Federal University (KFU) and the U.S.’ Rutgers University have launched a joint project in translational medicine. The project aims to address complex problems in personalized medicine, using most advanced bioinformatics and molecular biology methods, including the revolutionary CRISPR/cas9 genome editing technology, KFU .
The universities are said to have received a US-Russia University Partnership Program grant from the Eurasia Foundation.
The participants are the Institute of Fundamental Medicine and Biology at KFU and the Department of Biology in partnership with the Center for Computational and Integrative Biology at Rutgers.
The application was part of the new 7P Translational Medicine strategy of KFU. This strategy includes working on partnerships with leading overseas researchers, including members of the Russian-American Science Association (RASA).
KFU’s side will mostly be represented by the Tumor Pathogenesis Lab headed by Ilya Serebriiskii (Fox Chase Cancer Center). The Lab is part of the KFU-RASA Center for Translational Medicine.
Overseeing the effort are Prof. Ramziya Kiyamova from the Department of Biochemistry and Biotechnology on the part of KFU and Prof. Andrey Grigoriev at Rutgers.